Janice Suzann Drew sold $453k of EVMN
Chief of Dev. Operations at Evommune, Inc.. 20,000 shares at an average of $22.63, traded Jun 22, 2026, filed Jun 24, 2026.
Score components
- +15RoleOfficer
- +17Trade size$453k at market
- +5Share of holdings soldSold 23% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002091053-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | MOption exercise Common Stock10b5-1 | +3,839 | $3.84 | $15k | 71,633 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Common Stock10b5-1 | +16,161 | $2.99 | $48k | 87,794 | Jun 24, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stock10b5-1 | -20,000 | $22.63 | $453k | 67,794 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -3,839 | $0.00 | $0 | 53,795 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -16,161 | $0.00 | $0 | 39,321 | Jun 24, 2026 |
Related signals
Other insiders at Evommune, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 48Moderate | Evommune, Inc. | Kyle Carver Chief Financial Officer | $13k 1,000 shares | +2% | |
| 60Notable | Evommune, Inc. | Arthur S Kirsch director | $133k 10,000 shares | - | |
| 31Weak | Evommune, Inc. | Luis C. Pena President & CEO | $169k 7,438 shares | -1% | |
| 1Weak | Evommune, Inc. | Jeegar Pravinkumar Patel Chief Scientific Officer | $33k 1,488 shares | -3% | |
| 30Weak | Evommune, Inc. | David E Cohen director | $123k 6,056 shares | -26% | |
| 36Weak | Evommune, Inc. | Luis C. Pena President & CEO | $382k 16,787 shares | -3% | |
| 21Weak | Evommune, Inc. | Jeegar Pravinkumar Patel Chief Scientific Officer | $379k 16,687 shares | -26% | |
| 23Weak | Evommune, Inc. | Kyle Carver Chief Financial Officer | $415k 18,175 shares | -23% | |
| 14Weak | Evommune, Inc. | Gregory S. Moss Chief Business & Legal Officer | $325k 14,223 shares | -19% | |
| 21Weak | EVMNbuy Evommune, Inc. | Robert Lorne Hopfner director, owner | $17k 1,000 shares | +33% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.